BIO logo

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A

$291.55
$5.28
(1.82%)
Today
Closed $284.67
$6.88
(2.42%)
After Hours
Updated: 05:56 PM EDT
EarningsJul 30
Mkt Cap$7.81B
Vol206,955.00
News
all
press releases
Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories
Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.read more...
Benzinga
News Placeholder
More News
News Placeholder
Bio-Rad to Participate in Upcoming Investor Conferences
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following...
Business Wire
News Placeholder
Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?
Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Here's Why...
MarketBeat
News Placeholder
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell?
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened...
MarketBeat
News Placeholder
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendat...
MarketBeat
News Placeholder
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Zacks
News Placeholder
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price
Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday...
MarketBeat
News Placeholder
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...
MarketBeat
News Placeholder
Bio-Rad Laboratories Q1 Earnings Call Highlights
Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continued weakness in academic research demand are weighing on growth and profitability expectations for th...
MarketBeat
News Placeholder
Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) announced its quarterly earnings data on Thursday. The medical research company reported $1.89 earnings per share for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million during the...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.